GLP-1 medications (like semaglutide and tirzepatide, sold as Ozempic, Wegovy, Mounjaro, and Zepbound) do more than help with weight loss. They quiet food and craving signals in the brain, lower body-wide inflammation, and have been shown to cut heart attacks and strokes in adults with heart disease, even without diabetes.
In Medicine 2.0, we waited for you to get diabetes, then gave you a drug to manage it. In Medicine 3.0, we treat obesity as what it is: a problem with hormonal signaling rather than a personal failing.
GLP-1 medications (Ozempic, Wegovy, and Mounjaro) are the first tools that effectively rewrite that signaling.
How Do GLP-1 Medications Quiet "Food Noise"?
Patients tell me the same thing within 2 weeks of starting a GLP-1 plan:
"Dr. Ash, the radio in my head went quiet."
For decades, we told patients to "just eat less." For many, the brain's food noise (the constant, intrusive thought about the next meal) makes willpower physically hard.
GLP-1 receptors sit in the hypothalamus (the hunger control center) and the nucleus accumbens (the brain's reward and addiction hub). When we activate those receptors:
- Fullness signals get louder.
- The dopamine spike from rewards (food, alcohol, scrolling) gets quieter.
Can GLP-1s Help With Addiction Too?
This is some of the most interesting emerging science. Along with eating less, many patients report:
- Drinking less alcohol on their own.
- Less compulsive online shopping.
- Less nail biting and other repetitive habits.
By flattening the dopamine spike, GLP-1s appear to dial down the root mechanism behind compulsive behavior, whether the trigger is sugar, bourbon, or late-night Amazon scrolling.
There is a flip side, too: some patients describe a flatter emotional baseline (lower pleasure, motivation, or libido) on the same medications, sometimes called "Ozempic personality." For the full picture of GLP-1s and the brain, including the addiction signals and what to watch for, see GLP-1s and your brain.
What Did the SELECT Trial Show About the Heart?
The debate over "is this even healthy?" mostly ended in 2023 with the SELECT trial.
- The study. Over 17,000 patients with established heart disease, but no diabetes.
- The result. A 20% reduction in heart attacks, strokes, and cardiovascular death.
Fishtown Medicine
A 90-minute conversation with Dr. Ash. A written plan you can actually follow.
The benefit came from more than weight loss. The medication has its own anti-inflammatory effect on blood vessels. The FDA has now approved semaglutide as a heart medication, adding to its earlier approval for weight.
What Is the Fishtown "Micro-Dose" Strategy?
We do not believe in the "more is better" approach baked into standard dosing schedules. High doses can lead to:
- "Ozempic face." Rapid fat loss can deflate the face.
- Sarcopenia. Severe muscle loss that wrecks long-term metabolism.
- Anhedonia. A flat, joyless feeling, because dopamine is suppressed too far.
Our Approach
- Lowest effective dose. We titrate slowly. The goal is to quiet the noise while leaving appetite intact. You become indifferent to the donut rather than nauseous at the sight of it.
- Protein floor. You need around 1 gram of protein per pound of your target body weight. If you lose weight by burning muscle, you are aging yourself.
- Strength training. Heavy resistance work is non-negotiable. We are building a strong, capable body rather than a smaller one.
Is Using a GLP-1 "Cheating"?
I ask my patients, "Is wearing glasses cheating?"
If you are nearsighted, your biology fights your ability to see. You can squint harder, or you can use lenses that correct the focal length.
If you have leptin resistance (your brain stops hearing the "you are full" signal) or hyperinsulinemia (chronically high insulin), your biology fights your ability to regulate energy. You can try harder (and fail, like 95% of dieters), or you can use a tool that corrects the signaling.
The medication buys a behavioral window. While the noise is quiet, we build the habits (sleep, zone 2 cardio, whole foods, lifting). The drug is the runway. Your habits are the plane.
Guidance from the Clinic

Stop fighting your biology.
If you are ready to discuss a safe, monitored, engineering-based approach to metabolic health, let's talk.
Scientific References
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. (SELECT trial.)
- Volkow ND. GLP-1 receptor agonists for the treatment of substance use disorders. JAMA Psychiatry. 2023.
- Drucker DJ. GLP-1 physiology informs the pharmacologic potential of glucagon-like peptide-1. Mol Metab. 2022.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. (STEP-1 trial.)
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. (SURMOUNT-1 trial.)
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
Dr. Ash reads every intake himself, and answers questions personally - usually within a few hours.




